Greenwich LifeSciences (GLSI) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 136.2% versus a loss of 61.0%. Over five years, GLSI leads with a -41.8% price change compared with -58.8% for SPRY. ARS Pharmaceuticals is the larger company by market cap ($297.6 million vs $282.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | SPRY |
|---|---|---|
| Share price | $19.25 | $2.96 |
| Market cap | $282.56M | $297.56M |
| 1-day change | -2.73% | -11.90% |
| YTD return | -8.38% | -74.59% |
| 1-year return | +136.20% | -61.00% |
| 5-year return | -41.84% | -58.83% |
| EPS (TTM) | $-1.63 | $-2.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $84.28M |
| Revenue growth (YoY) | — | -5.46% |
| Net income (latest FY) | $-19.36M | $-171.30M |
| Operating margin | — | -212.92% |
| Net margin | — | -203.25% |
| 52-week high | $34.10 | $13.15 |
| 52-week low | $7.78 | $2.44 |
| Distance from 52-week high | -43.55% | -77.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +198.70% | +474.32% |
| Average volume | 160.76K | 1.83M |
| Shares outstanding | 14.68M | 100.53M |
| Employees | — | 203 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed SPRY by 197.2 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees
GLSI vs SPRY FAQ
Which is bigger, Greenwich LifeSciences or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $297.56M compared with $282.56M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or SPRY?
GLSI returned +136.20% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.